Search by Drug Name or NDC
NDC 46287-0045-15 TADLIQ 20 mg/5mL Details
TADLIQ 20 mg/5mL
TADLIQ is a ORAL SUSPENSION in the HUMAN PRESCRIPTION DRUG category. It is labeled and distributed by CMP Pharma, Inc.. The primary component is TADALAFIL.
Product Information
| NDC | 46287-0045 |
|---|---|
| Product ID | 46287-045_8389ef2b-e4b4-4fa2-8d1a-157f514d7786 |
| Associated GPIs | |
| GCN Sequence Number | 083592 |
| GCN Sequence Number Description | tadalafil ORAL SUSP 20 MG/5 ML ORAL |
| HIC3 | B1D |
| HIC3 Description | PULM.ANTI-HTN,SEL.C-GMP PHOSPHODIESTERASE T5 INHIB |
| GCN | 52585 |
| HICL Sequence Number | 024859 |
| HICL Sequence Number Description | TADALAFIL |
| Brand/Generic | Brand |
| Proprietary Name | TADLIQ |
| Proprietary Name Suffix | n/a |
| Non-Proprietary Name | Tadalafil |
| Product Type | HUMAN PRESCRIPTION DRUG |
| Dosage Form | SUSPENSION |
| Route | ORAL |
| Active Ingredient Strength | 20 |
| Active Ingredient Units | mg/5mL |
| Substance Name | TADALAFIL |
| Labeler Name | CMP Pharma, Inc. |
| Pharmaceutical Class | Phosphodiesterase 5 Inhibitor [EPC], Phosphodiesterase 5 Inhibitors [MoA] |
| DEA Schedule | n/a |
| Marketing Category | NDA |
| Application Number | NDA214522 |
| Listing Certified Through | 2024-12-31 |
Package
NDC 46287-0045-15 (46287004515)
| NDC Package Code | 46287-045-15 |
|---|---|
| Billing NDC | 46287004515 |
| Package | 150 mL in 1 BOTTLE (46287-045-15) |
| Marketing Start Date | 2022-08-30 |
| NDC Exclude Flag | N |
| Pricing Information | N/A |